Blood disorders develop when the body makes too many or not enough red blood cells, white blood cells or platelets. Some of these disorders are not leukemias, but they can increase the risk of developing leukemia.
Myeloproliferative neoplasms @(Model.HeadingTag)>
In myeloproliferative neoplasms, the body makes too many of, or overproduces, 1 or more types of blood cells. The overproduction starts when a single blood stem cell changes, or mutates, and reproduces. Certain myeloproliferative neoplasms may become acute myelogenous leukemia (AML).
There are 6 types of myeloproliferative neoplasms:
- polycythemia vera (PV), which is also called polycythemia rubra vera
- idiopathic myelofibrosis (IM), which is also called primary myelofibrosis
- essential thrombocytosis (ET), which is also called essential thrombocythemia
- chronic myelogenous leukemia (CML)
- chronic neutrophilic leukemia (CNL)
- chronic eosinophilic leukemia (CEL)
CML is the most common leukemia that is considered a myeloproliferative neoplasm. Find out more about chronic myelogenous leukemia (CML).
Myelodysplastic syndromes @(Model.HeadingTag)>
Myelodysplastic syndromes are diseases in which the bone marrow does not make enough healthy mature blood cells. The immature blood cells, called blasts, do not work properly. They build up in the bone marrow and the blood. As a result, there are fewer healthy red blood cells, white blood cells and platelets.
Myelodysplastic/myeloproliferative neoplasms @(Model.HeadingTag)>
Myelodysplastic/myeloproliferative neoplasms have characteristics of both myelodysplastic syndromes and myeloproliferative neoplasms.
The following are types of myelodysplastic/myeloproliferative neoplasms:
- chronic myelomonocytic leukemia (CMML)
- atypical chronic myelogenous leukemia (aCML)
- myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-UC)
Dawson MA, Huntly JP . The pathogenesis, diagnosis, and treatment of polycythaemia vera. Wiernik PH, Goldman JM, Dutcher JP & Kyle RA (eds.). Neoplastic Diseases of the Blood. 5th ed. Springer; 2013: 11: p. 135-153.
Kurtin SE . Leukemia and myelodysplastic syndromes. Yarbro, CH, Wujcki D, & Holmes Gobel B. (eds.). Cancer Nursing: Principles and Practice. 7th ed. Sudbury, MA: Jones and Bartlett; 2011: 57: pp. 1369-1398.
National Cancer Institute. Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®) Health Professional Version. Bethesda, MD: National Cancer Institute; 2014.
National Cancer Institute. Chronic Myeloproliferative Neoplasms Treatment (PDQ®) Health Professional Version. 2015: http://www.cancer.gov/cancertopics/pdq/treatment/myeloproliferative/HealthProfessional.
Reilly JT . Diagnosis and treatment of essential thrombocythemia and primary myelofibrosis. Wiernik PH, Goldman JM, Dutcher JP & Kyle RA (eds.). Neoplastic Diseases of the Blood. 5th ed. Springer; 2013: 12: p. 155-168.